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Summary The SCC-25 cell line is a well-established line derived from a human squamous carcinoma of the
head and neck. The capacity of this cell line for recovery from potentially lethal damage following X-ray
treatment has been documented. The survival curve of stationary phase SCC-25 cells exposed to various
concentrations of bleomycin is biphasic with an initial sensitive phase and a less sensitive second phase as is
common for many cell lines. Stationary phase SCC-25 cells were exposed to lOOmUml-1 of bleomycin for
I h. The drug was removed and the cells were allowed various periods to recover from potentially lethal
damage. After 24h, the SCC-25 cells showed a recovery ratio (RIRO) of 7.0 which corresponded to an
immediate survival at a drug level of 27mUml-1, a dose 3.7-fold less than the exposure concentration of
100mUml- . Over the course of the first 4h following bleomycin exposure, 0.5pM CDDP was a very
effective inhibitor of potentially lethal damage repair, giving a R/Ro of 1.1 or nearly complete inhibition
of recovery. Between 2 and 4h the R/Ro was 1.6-1.8 with CDDP and 4.1-5.3 without CDDP indicating
appeciable inhibition of recovery. Plant (lOpuM) and Plato (IOpM) produced potentially lethal damage
recovery inhibition patterns very similar to that of CDDP. After 1 h the recovery ratios in the presence of
Plant and Plato were 1.1-1.3. Between 2 and 4 h, Plato and Plant gave recovery ratios of 1.8-2.3 and 1.6-1.9,
respectively. NIPt and Pt(terpy) were examined at both 10pM and 25pM for their ability to inhibit potentially
lethal damage recovery after bleomycin treatment. After I h, NIPt gave a recovery ratio of 1.3-1.4, and after
2-4h the recovery ratio was 1.7-2.6. Pt(terpy) gave recovery ratios of 1.3-1.6 after 1 h and 1.5-1.8 after 24h.
The antibiotic complex bleomycin has been shown to exhibit
clinical usefulness in the treatment of squamous cell cancer
of the head and neck (SCCHN). Clinical efficacy has been
noted in both palliative treatment of advanced disease and
when administered prior to irradiation and/or surgery. Given
as a single agent in the treatment of recurrent disease,
response rates ranged from 6% to 45% with a short
duration of remission (Turrisi et al., 1978). However, when
administered concomitantly with radiation therapy,
bleomycin did not increase either response rate or survival
time when compared to radiation therapy alone. Severe
mucosal reactions in the majority of patients required
discontinuation of therapy (Shah et al., 1981). The lack of
haematopoietic and hepatic toxicities suggested that
bleomycin could be used in combination with other drugs
giving significant response rates in patients with previously
treated SCCHN (Ervin et al., 1981). Recently, multiple drug
regimens which include bleomycin have been shown to
exhibit activity when given preoperatively and/or prior to
irradiation. In combination with CDDP and methotrexate or
vincristine, response rates range from 58% to 90% (Boeheim
& Spoendlin, 1984; Spaulding et al., 1982). Despite these
high response rates, a proportion of patients did not
respond. Additionally, drug resistance, upon tumour
recurrence, has arisen in all patients treated with
chemotherapy alone.
The present paper reports in vitro characteristics of the
effects of bleomycin on a well characterized, human
squamous cell carcinoma cell line cultured from biopsies of
head and neck malignancies. We employed cells growing at
low density for the determination of bleomycin responsive-
ness in exponentially growing cells. However, such
exponentially growing cells account for only a portion of the
total cell population of in vivo malignancies. A solid tumour
contains a large fraction of non-cycling cells, therefore an in
vitro system containing cells in plateau phase may be more
analogous to the in vivo situation. Such an experimental
model can be obtained when monolayers of mammalian cells
are grown to confluency under conditions of constant
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medium renewal without subculture. These plateau-phase
cultures contain a large fraction of non-cycling, but
potentially clonogenic, cells (Hahn & Little, 1972). In such
cultures, enhancement of cell survival may be observed when
cells are allowed to repair by delaying cell subculture after
exposure to chemical agents or X-rays. Any increase of cell
survival after such treatment is referred to as potentially
lethal damage repair (PLDR) (Ray et al., 1973;
Weichselbaum et al., 1982). We have employed a human
squamous cell carcinoma cell line (SCC-25) to study PLDR
following bleomycin treatment. We also have examined the
influence of cis-diamminedichloroplatinum(II) (CDDP) and
several other platinum complexes on bleomycin-induced
PLDR. The effect of these drugs on PLDR following
bleomycin treatment is of particular interest, since
combinations of bleomycin and CDDP have shown
enhanced efficacy in the treatment of SCCHN (Glick et al.,
1980; Hong et al., 1980; Wittes et al., 1979).
Materials and methods
Reagents
Bleomycin (Blenoxane®R) was obtained as a gift from Bristol
Laboratories, Syracuse NY. Cis-diamminedichloro-
platinum(II) (CDDP) was obtained as pure powder as a
gift from Dr D.H. Picker, Johnson-Matthey Inc., West Chester
PA. The platinum terpyridine complex [Pt(terpyrdine)Cl]Cl
[Pt(terpy)] was obtained as the pure powder as a gift
from Dr M.J. Abrams, Johnson-Matthey Inc., West Chester
PA. The other platinum complexes [trans-di(2-amino-5-
nitrothiazole)dichloroplatinum(II) (Plant), cis-(1,2-diamino-
4-nitrobenzene)dichloroplatinum(II) (Plato), and trans-di(2-
nitroimidazole)dichloroplatinum(II) (NIPt)] were prepared in
our laboratory as previously described (Teicher et al., 1985).
Cell line
The SCC-25 cell line was derived from the biopsy of a
human squamous cell carcinoma of the tongue and was
established and characterized initially by J.G. Rheinwald at
this Institute (Rheinwald & Beckett, 1981). Monolayers were
Br. J. Cancer (1987), 55, 245-248 D(- The Macmillan Press Ltd., 1987246 S.A. HOLDEN el al.
maintained in Dulbecco's modified Eagle's medium
(DMEM) supplemented with 5% foetal bovine serum,
hydrocortisone (0.4jgml- 1) and antibiotics (Frei et al.,
1985; Teicher et al., 1986). This cell line has a plating
efficiency of 10-30% and a doubling time of 48 h (Frei et al.,
1985).
Survival studies
SCC-25 cells were grown to confluency, then the culture
medium was renewed daily for 3 days and experiments were
performed on the following day. After exposure to the drug
or vehicle for I h, the cells were washed 2 times with 0.9%
PBS and suspended by treatment with 0.125% trypsin/0.05%
EDTA. The cells were plated in duplicate dishes at 3
dilutions for colony formation. After 2 weeks, the colonies
were visualized by staining with crystal violet and colonies of
50 cells or greater were counted. The results are expressed
as surviving fraction of treated cells compared to vehicle-
treated control cells.
Survival studiesfor PLDR
Stationary phase cultures of SCC-25 cells were prepared as
described above. The cells were exposed to 100mUml-1 of
bleomycin for 1 h at 37°C in fresh medium. The medium
covering the monolayers before treatment (depleted medium)
was retained and used to cover the cultures during the delay
from subculture period. After treatment with bleomycin, the
dishes were rinsed twice with PBS and depleted medium was
added. Platinum complexes were added to the depleted
medium for the duration ofthe delay to the time ofsubculture.
The concentrations of platinum complexes were 0.5 iM
CDDP, 10/uM Plant, 10 IM Plato, 10gM and 25gM NIPt and
10 IM and 25 pM Pt(terpy). Similar dishes which had not
been treated with bleomycin were exposed to the platinum
complexes for the same time periods to assess the cytotoxicity
of the platinum complexes alone. Both treated and control
dishes were held for 0, 1, 2, 4, 6 and 24 h at 37°C, then the
cells were washed twice with PBS, suspended by trypsiniz-
ation and counted by hemacytometer. Known numbers of
cells were plated in duplicate dishes at 3 dilutions for
colony formation as described above.
Data analysis
Quantitative analysis of survival curves was performed using
the log-probit iterative least squares method of Litchfield
and Wilcoxon (1949) as revised by Tallarida and Murray
(1981). Calculations were performed on an Apple II +
microcomputer.
Recovery ratios (R/RO) were calculated by dividing the
surviving fraction immediately after drug exposure (RO) into
the surviving fraction of cells at each time post-treatment (R)
corrected for the cytotoxicity of the inhibitor. A recovery
ratio of 1.0 means no recovery or repair of damage and a
ratio of greater than 1.0 means recovery from PLD
(Barranco & Townsend, 1986).
Results
The SCC-25 cell line is a well-established line derived from a
human squamous carcinoma of the head and neck. The
capacity of this cell line for PLDR following X-ray
treatment has been documented with a 24h recovery ratio
(R/RO) of 6.2 (Weichselbaum, 1984). Figure I shows the
survival curve for stationary phase SCC-25 cells exposed to
various concentrations of bleomycin. The survival curve is
biphasic with an initial sensitive phase and a less sensitive
second phase as is common for many cell lines (Twentyman,
1984). After stationary phase SCC-25 cells were exposed to








o 2 4 6 24
PLD recovery (h)
Bleomycin conc., mU ml
Figure 1 Survival curve for stationary phase SCC-25 cells
treated with various concentrations of bleomycin for 1 h (0).
Inset: PLD recovery (0) showing the loss of effectiveness of
bleomycin (1OOmUml-1) due to recovery from potentially lethal
damage over 24h. Error bars are s.e.
and the cells were allowed various periods for PLD recovery.
After 24h, the SCC-25 cells showed a recovery ratio (R/RO)
of 7.0 which corresponded to an immediate survival at a
drug level of 27mU ml -, a dose 3.7-fold less than the
exposure concentration of 100mUml-1. The recovery ratio
for SCC-25 cells following bleomycin treatment increased
rapidly at early time points. It was 2.5 at 1 h, 4.1 at 2h and
5.3 at 4h. The rate of recovery slowed after 4h so that the
recovery ratio was 6.1 at 6 h and 7.0 at 24h.
Over the course of the first 4h of PLD recovery, 0.5,UM
CDDP was a very effective inhibitor of PLDR (Figure 2).
For the first hour, while R/Ro was 2.5 for bleomycin alone,
with 0.5gM CDDP the R/Ro was 1.1. Between 2 and 4h the
R/Ro was 1.6-1.8 with CDDP and 4.1-5.3 without CDDP.
However, at the 6h point the cell survival in the presence of
CDDP increased, producing a recovery ratio of 3.9 with
CDDP compared to 6.1 without CDDP. Plant (1OpM) and
Plato (10,UM) produced PLD recovery inhibition patterns
very similar to that of CDDP. After 1 h the recovery ratios
in the presence of Plant and Plato were 1.1-1.3. Between 2
and 4h, Plato gave recovery ratios of 1.8-2.3 and Plant gave
recovery ratios of 1.6-1.9. By 6h both Plato and Plant were
less effective inhibitors than CDDP, producing recovery
ratios of 5.3 and 4.4 respectively.
NIPt and Pt(terpy) were examined at both 10pgM and
25 pM for their ability to inhibit PLD recovery after
bleomycin treatment (Figure 2). There was no significant
difference between PLDR inhibitory effects by the different
concentrations of these agents. After 1 h, NIPt gave a re-
covery ratio of 1.3-1.4, at 2-4 h the recovery ratio was 1.7-
2.6 and at 6h the recovery ratio was 3.6-3.8. Pt(terpy) gave
recovery ratios of 1.3-1.6 after I h, 1.5-1.8 at 2-4h and 3.5-
4.0 at 6h. With NIPt and Pt(terpy), there was a continuous
increase in the recovery ratios compared to the more
stepwise increase in recovery ratios with CDDP, Plant and
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Figure 2 Panels a-c: Survival of stationary phase SCC-25 cells treated with 100uM bleomycin which were allowed various
periods of time for PLD recovery (*). Panel a: Survival of these same cells exposed to 0.5pM CDDP (-), 10OpM Plant (-) or
10/pM Plato (A) during the PLDR recovery period. Survival of untreated cells exposed to 0.5pM CDDP (0), 10/pM Plant (Ol)
or 10pM Plato (A) for the indicated time periods. Panels b and c: Survival of these same cells exposed to 10 pM NIPt (0), 25 pM
NIPt (*), 1OpM Pt(terpy) (A) or 25 pM Pt(terpy) (U) during the PLDR recovery period. Survival of untreated cells exposed to
IO0pM NIPt (0), 25 pM NUPt(terpy) (O) or 25 jiM Pt(terpy) (El) for the indicated time periods. Error bars are the s.e.
Discussion
The significance of PLDR has remained controversial
(Twentyman, 1984; Weichselbaum et al., 1982; Weichselbaum
et al., 1984); however, it seems reasonable that drug
combinations which inhibit the ability of tumour cells to
repair significant portions of drug-induced damage will lead
to improved clinical treatment. The ability of mammalian
cells to recover from bleomycin-induced damage has been
well-documented both in vitro and in vivo (Barranco &
Townsend, 1986). The process can be inhibited with actino-
mycin D, ethanol and hyperthermia (Barranco, 1978;
Twentyman, 1984) or under hypoxic conditions by miso-
nidazole (Korbelik et al., 1985). More recently it has been
shown that some platinum complexes can inhibit the recovery
of V79 cells from radiation-induced cell kill (O'Hara
et al., 1986). We have shown that CDDP and four other
novel platinum complexes can inhibit to a moderate degree
PLD recovery of stationary phase SCC-25 cells treated with
bleomycin. Increased repair is one possible mechanism of
resistance to chemotherapeutic agents (Teicher et al., 1986).
Drug combinations which can inhibit these repair processes
and overcome resistance would be of great value in the
clinic. The platinum complexes used in this study have been
previously shown to potentiate the cytotoxicity of mitomycin
C, especially in hypoxic cells (Teicher et al., 1986). It is
possible, therefore, to speculate on the possibility of a drug
combination including euoxic and hypoxic selective drugs
such as bleomycin/mitomycin C and at low doses a platinum
complex which may inhibit potentially lethal damage
recovery from bleomycin cytotoxicity and potentiate
mitomycin C cytotoxicity. Our data suggest new avenues for
therapeutic research in SCCHN. Since repair of SCC-25 cells
after treatment with bleomycin begins 1-2h after treatment,
fractionated doses or long term infusion of bleomycin as
proposed by Umezawa (1982) or intermittent large dose
treatment may be superior. Also, since the addition of
relatively non-toxic doses of the platinum complexes to
bleomycin resulted in a significant reduction of PLD repair,
the addition of other chemotherapeutic drugs such as CDDP
may further enhance the therapeutic efficacy of bleomycin
treatment of tumours.
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